Pancreatic Cancer Research

ResearcherTUM KlinikumActive in the last 2 years

Sebastian Lange

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0406-1401; OpenAlex author ID A5039122987. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
104
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41551-024-01273-9↗
  2. Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO … Co-author DOI 10.1007/s00432-024-05954-5↗
  3. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  4. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-319970↗
  5. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. First author DOI 10.1172/jci.insight.141532↗
  6. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  7. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  8. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Co-author DOI 10.1038/nature25459↗
  9. siRNA-coupled nanoparticles for improved therapeutic targeting of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-312092↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maximilian Reichert · 5 shared papers, 2020–2025 · strength 0.58
  2. Roland Rad · 6 shared papers, 2016–2025 · strength 0.57
  3. Roland Michael Schmid · 5 shared papers, 2018–2025 · strength 0.48
  4. Dieter Saur · 5 shared papers, 2016–2025 · strength 0.48
  5. Rickmer Braren · 4 shared papers, 2020–2025 · strength 0.43
  6. Günter Schneider · 4 shared papers, 2018–2025 · strength 0.38
  7. Katja Peschke · 3 shared papers, 2020–2025 · strength 0.33
  8. Wilko Weichert · 4 shared papers, 2018–2022 · strength 0.33
  9. Hana Algül · 3 shared papers, 2020–2021 · strength 0.24
  10. Georgios A. Kaissis · 2 shared papers, 2020–2025 · strength 0.22
  11. Aristeidis Papargyriou · 2 shared papers, 2020–2025 · strength 0.22
  12. Irina Heid · 2 shared papers, 2020–2025 · strength 0.22
  13. H. Carlo Maurer · 2 shared papers, 2021–2022 · strength 0.21
  14. Helmut Friess · 2 shared papers, 2021–2022 · strength 0.21
  15. Sebastian Mueller · 2 shared papers, 2018–2025 · strength 0.20
  16. Felix Orben · 2 shared papers, 2020–2022 · strength 0.18
  17. Christoph Schlag · 2 shared papers, 2020–2022 · strength 0.18
  18. Lucia Liotta · 2 shared papers, 2020–2021 · strength 0.17
  19. Alexander Muckenhuber · 2 shared papers, 2020–2021 · strength 0.17
  20. Christian Schneeweis · 1 shared paper, 2025 · strength 0.15
  21. Sophie Dobiasch · 1 shared paper, 2025 · strength 0.15
  22. Stefanie Bärthel · 1 shared paper, 2025 · strength 0.15
  23. Jacco van Rheenen · 1 shared paper, 2025 · strength 0.15
  24. Andreas R. Bausch · 1 shared paper, 2025 · strength 0.15
  25. Stephanie Elisabeth Combs · 1 shared paper, 2025 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.